SecBot SecBot
Institutional Cluster

RCUS

Arcus Biosciences, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed7d 16h ago
Institutional cluster: 5 buyers, 1 sellers (bullish)
Actionable Insight • Neutral

The Q3 cluster shows conviction from active asset managers ahead of positive casdatifan data, but the October $250M equity offering at $17.50 (below the Q3 average cost) likely diluted these positions. Monitor Q4 13F filings to see if the buyers held or exited post-offering.

DirectionNeutral
Confidencemedium
Horizonweeks

casdatifan

◆ Mixed Named in this fund cluster
Impact
Phase
Phase 2
Time to market
Estimated 3-5 years. The drug is in Phase 2; a Phase 3 registrational trial has not yet been initiated. Even with a potential accelerated path, FDA submission is likely several years away.
Next catalyst
None dated

What to watchWatch for the next ARC-20 data update at a medical conference (likely 2027) and any announcement of a Phase 3 registrational trial start. The $250M capital raise at a discount signals near-term cash needs despite positive data; monitor for further dilution risk. The stock is technically oversold (RSI 27.5) with strong analyst support, but no hard binary catalyst is scheduled within the next 12 months.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$18.95
T+0 close · Nov 9, 2026 · via day close
Latest settled
−11.03%
T+5 · $16.86
Vs SPY
−9.34%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $18.95entry
  2. T+1 · 7d ago −1.48%α −1.11% · $18.67
  3. T+5 · 20h ago −11.03%α −9.34% · $16.86
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Five institutional investors added $9.8M in RCUS during Q3 2026, led by Aberdeen Group doubling its stake to $27.3M, while Citigroup trimmed $2.0M. The cluster follows positive casdatifan Phase 2 data and a $250M October equity offering, but the 45-day reporting lag means positions may have shifted since quarter-end.

Key Financial Metrics

Direction
accumulating
Buy Value
$33.2M
Sell Value
$3.5M
Net Flow
$9.8M

Institutional Positions

Net institutional flow: $9.8M

▲ Buyers (5)

InstitutionActionChangePosition ValueValue Δ
Aberdeen GroupADD+62.4%$27.3M$7.2M
BarclaysDOUBLED+340.3%$2.2M$1.6M
Russell Investments GroupADD+65%$3.5M$961.0K

▼ Sellers (1)

InstitutionActionChangePrev ValueValue Δ
CitigroupTRIM-49.9%$3.5M-$2.0M

Key Facts

  • 5 institutional buyers added net $9.8M in Q3 2026, 1 seller reduced $2.0M
  • Aberdeen Group was the largest buyer, adding $7.2M to reach $27.3M (a 62.4% increase)
  • Barclays more than quadrupled its position (+340.3%), adding $1.6M
  • Citigroup trimmed 49.9% of its stake, reducing by $2.0M
  • 13F data is 45+ days stale; the October equity offering and subsequent price action may have altered positions
  • No open-market insider buying corroborates the cluster (confluence score 18/100)

Financial Impact

5 institutions accumulated $9.8M in net new positions while 1 institution reduced holdings by $2.0M

institutional ownership

Risk Factors

  • 13F data is stale by 45+ days; positions may have been unwound after the October equity offering
  • No insider buying to corroborate the institutional signal
  • Revenue declined 65% YoY in the most recent quarter due to the Gilead collaboration wind-down

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-RCUS-2026-Q3

Track record

13 reports on RCUS

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +4.24% at T+1 after the Oct 21, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $16.95 settles Nov 23
  2. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Viewing Entry $18.95 to $16.86 ▼ −11.03% −9.34% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $17.69 to $17.77 ▲ +0.45% −2.84% vs SPY
  4. Oct 23, 202624d ago 8-K Bearish 5/10 Entry $17.76 to $18.19 ▼ −2.42% −3.68% vs SPY
  5. Oct 22, 202625d ago 424B5 Bearish 6/10 Entry $18.54 to $18.19 ▲ +1.89% +1.33% vs SPY
  6. Oct 21, 202626d ago 424B5 Bearish 5/10 Entry $19.36 to $18.61 ▲ +3.87% +4.58% vs SPY
  7. Oct 21, 202626d ago 8-K Neutral 4/10 Entry $19.36 to $18.61 ▼ −3.87% −4.58% vs SPY
  8. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $23.75 to $18.14 ▼ −23.62% −23.70% vs SPY
  9. Jul 9, 202618w ago 144 Neutral 3/10 Entry $28.92 to $26.64 ▼ −7.88% −7.32% vs SPY
  10. Apr 21, 202629w ago DEFA14A Neutral 2/10 Entry $26.62 to $24.55 ▼ −7.79% −7.85% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026